A concurrent analysis of 19 trials of PD-1 and PD-L1 for NSCLC found that PD-1 inhibitors revealed an increase in the incidence of pneumonia of any grade and grade ≥ 3 in comparison with PD-L1 inhibitors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.